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Objectives. To evaluate the effects of iloprost, in addition to surgery, on the outcome of acute lower limb ischemia (ALLI).
Design. Post-hoc analysis of a randomized, double-blind, placebo-controlled study.
Methods. In the context of the ILAILL (ILoprost in Acute Ischemia of Lower Limbs) study, 192 elderly patients (>70 years
old) undergoing surgery for ALLI were assigned to receive perioperative iloprost (intra-arterial, intra-operative bolus of
3000 ng, plus intravenous infusion of 0.5e2.0 ng/kg/min for six hours/day for 4e7 days following surgery), or placebo
(iloprost: n¼ 100; placebo: n¼ 92). Patients were followed-up for three-months following surgical revascularization.
Results. The combined incidence of death and amputation (primary study end-point) was significantly reduced in patients
treated with iloprost (16.0% vs 27.2% in the placebo group; hazard ratio 1.99, 95% confidence interval 1.05e3.75,
p¼ 0.03). A statistically significant lower mortality (6.0%) was reported in patients receiving iloprost, compared to con-
trols (15.2%) (hazard ratio 2.93, 1.11e7.71, p¼ 0.03). The overall incidence of death and major cardiovascular events was
lower in patients receiving iloprost compared to those assigned placebo (24.0% and 35.9%, respectively), at the limits of
statistical significance (relative risk 1.64, 0.97e2.79, p¼ 0.06).
Conclusions. These results confirm the poor outcome in elderly patients with ALLI. Based on a subgroup analysis iloprost,
as an adjuvant to surgery, appears to reduce the combined end-point of death and amputation.
Keywords: Acute limb ischemia; Elderly patients; Iloprost; Surgical revascularization; Reperfusion.Introduction
Acute lower limb ischemia (ALLI) continues to be as-
sociated with a high morbidity and mortality despite
improvements in perioperative care.1 Elderly patients
are at particular high risk of severe local and systemic
complications.2 Co-morbidity, the metabolic derange-
ment associated with acute ischaemia and reperfusion
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Due to its pharmacological profile, iloprost, a synthetic
prostacyclin analogue, is a candidate as adjuvant
treatment in patients with ALLI.4 Under the endorse-
ment of Italian Society for Vascular and Endovascular
Surgery (S.I.C.V.E.), we performed a randomized,
placebo-controlled, phase III study (ILAILL), to assess
the effects of perioperative treatment with iloprost in
300 patients with ALLI undergoing surgical revascu-
larization (thromboembolectomy or by-pass, in native
vessel or graft). In this study a significant reduction of
mortality and incidence of total major cardiovascular
events was shown in patients treated with iloprost.5
The incidence of combined death and amputation in
the ILAILL study was significantly related to agerved.
195Adjuvant Iloprost in Elderly Patients with Acute Limb Ischemia(21.3% in patients > 70 years, vs 9.3% in patients less
than 70 years, p< 0.01). As a post-hoc analysis we
therefore focused our attention on the effects of ilo-
prost as adjuvant to surgery in this group of elderly
patients with a high rate of complications.
Materials and Methods
One-hundred and ninety-two patients (92 in the
placebo and 100 in the iloprost group) over 70 years
old were enrolled in ILAILL. Patients were considered
for inclusion if they presented with acute onset (less
than 14 days) of symptoms suggestive of ischemia of
lower limbs (native vessels and/or graft occlusions)
and were to be treated with surgical revasculariza-
tion. Patients with lower limb ischemia due to trauma
were excluded. Other exclusion criteria included:
acute myocardial infarction or stroke within the last
6 months prior to enrolment; cardiac failure (NYHA
Class > I); unstable angina; angina pectoris (Canadian
classification > II); hyperkinetic ventricular arrhyth-
mias; severe hypertension (sitting systolic blood
pressure 180 mmHg or diastolic blood pressure
110 mmHg) or hypotension (systolic blood pressure
<90 mmHg); haemorrhagic diathesis; concomitant
clinical conditions in which iloprost might increase
the risk of bleeding (i.e. active peptic ulcer, trauma, ce-
rebral haemorrhage); thrombocytopenia (<80.000/mm3)
or thrombocytosis (>500.000/mm3); severe hepatic
failure (cirrhosis); renal failure requiring dialysis
treatment.
Iloprost (Endoprost, Italfarmaco S.p.A., Milan,
Italy, under licence of Schering AG, Berlin, Germany)
or placebo were administered as an intra-arterial
bolus of 3000 ng over 1e3 minutes immediately after
revascularization and in the same affected artery.
Starting from the first day after surgery, a daily
6-hour intravenous infusion of iloprost (or placebo)
at doses of 0.5e2.0 ng/kg/min was performed for
4e7 days (7 days recommended), depending on the
length of hospital stay. Patients were followed-up
for 90 5 days after surgery, for occurrence of major
clinical events. The primary efficacy end-point of
ILAILL was the combined incidence of death and
amputation during a three-month follow-up period.
Secondary efficacy end-points were the incidence of
each single major clinical event (acute myocardial
infarction, stroke, peripheral embolism, pulmonary
embolism, other major cardiovascular events, ampu-
tation and death) during the study, and the total event
rate (death plus major cardiovascular events).
Baseline continuous variables were compared be-
tween the two treatment groups by unpaired t-test,
categorical variables were compared by Chi-squaretest or Fisher exact test, as appropriate. Multivariable
analyses, adjusting for potential confounders, were
performed using the Cox proportional hazard reg-
ression model, to compare the outcomes (combined
deathþ amputation, death, total event rate) in the
two treatment groups. Apart from experimental treat-
ment (placebo vs iloprost), the following variables
were selected for the multivariable analyses, on the
basis of their clinical importance: duration of ischemia
(>24 hours vs  24 hours); class of ischemia according
to SVSeISCVSeTASC criteria1,6 (IIb-III vs IIa-I); previ-
ous cardiovascular event(s) (acute myocardial ische-
mia, stroke, peripheral revascularization, yes vs no);
type of surgery (thromboembolectomy vs other mo-
dalities). Proportional hazard assumption were tested
for all the covariates included and no relevant viola-
tions were found. All statistical tests were two-sided
and p-values below 0.05 were considered as signi-
ficant. Statistical analyses were performed by using
SAS software (version 8.2, SAS Institute, Cary, NC,
USA), on the basis of the intention-to-treat.
The study was conducted according to the ethical
principles stated in the Declaration of Helsinki and
local regulations. The protocol was approved by the
Ethics Committee of each participating center, and
written informed consent was obtained by all patients
before randomization.
Further details on study design, and overall results
of the trial, have been described elsewhere.5
Results
Baseline characteristics of the two groups of patients
were similar (Table 1). The duration of treatment did
not differ between the experimental and control group
(Table 2). Concomitant therapies during follow-up
were very similar for the two groups (heparin 83.7%
and 85.0%, oral anticoagulants 27.2% and 29.0%, anti-
platelet therapies 27.2% and 24.0%, anti-hypertensive
52.2% and 56.0% in placebo and iloprost groups,
respectively). Withdrawal from study without com-
pletion of follow-up and without occurrence of
major clinical events requiring study discontinuation
occurred in 13.0% and 12.0% of patients in the placebo
and iloprost group, respectively, due to Investigator’s
judgement of lack of effect (6.5% for placebo and
3.0% for iloprost), non-compliance or patient lost to
follow-up.
The incidences of outcomes and the relevant results
of the multivariable analyses (Cox regression model)
are reported in Fig. 1. The combined incidence of
death and amputation (primary study end-point)
was significantly reduced in patients treated with
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ratio 1.99, 95% confidence interval 1.05e3.75, p¼ 0.03).
A statistically significant lower mortality (6.0%) was
reported in patients receiving iloprost, compared to
controls (15.2%) (hazard ratio 2.93, 1.11e7.71, p¼ 0.03).
The Kaplan-Meier curve for survival is shown in
Fig. 2. The overall incidence of fatal plus major
cardiovascular events was lower in iloprost patients
vs placebo group (24.0% and 35.9%, respectively), at
the limits of statistical significance (relative risk 1.64,
0.97e2.79, p¼ 0.06). In Table 3 more specific informa-
tion on the major complications are shown.
On multivariable analysis, occurrence of death or
amputation appeared significantly related to class
of ischemia (IIb), and less frequent for patients
undergoing thromboembolectomy (vs other surgical
procedures) (Table 4). No serious adverse reactions
occurred after iloprost administration, nor significant
Table 1. Baseline characteristics of patients. All comparison
between study groups were statistically non-significant*. PAD[
peripheral arterial disease
Characteristic Placebo
(N¼ 92)
Iloprost
(N¼ 100)
Age e yr 81.0 6.5 80.3 6.1
Sex e M/F 47/45 50/50
Medical history/Concomitant
conditions (%)
Ischemic cardiopathy 22.8 24.0
Cerebrovascular disease 27.2 23.0
Atrial fibrillation/arrhythmias 59.8 57.0
Chronic PAD 12.0 18.0
Prev. revascularization lower limb(s) 22.8 28.0
Hypertension 69.6 64.0
Diabetes 17.4 15.0
Tumor 16.3 22.0
Duration of symptoms (%)
0e6 hrs 15.3 19.2
6e24 hrs 37.4 38.4
>24 hrs 47.3 42.4
Clinical category of acute ischemia (%)
Class IeIIa 33.7 36.5
Class IIbeIII 66.3 63.5
Type of intervention (%)
Thromboembolectomy 78.3 77.8
By-pass 15.2 16.2
Combined 6.5 6.0
*comparison between treatment groups, t-test or Chi square test, as
appropriate.
Table 2. Duration of experimental treatment for the two study
groups
Duration of treatment Placebo
(% of patients)
Iloprost
(% of patients)
p value
Bolus/ 3 days 15.2 12.0 ns
4 days 35.9 40.0 ns
5e6 days 5.4 6.0 ns
7 days 43.5 42.0 ns
Eur J Vasc Endovasc Surg Vol 34, August 2007differences in the incidence of bleeding (2.2% placebo vs
3.0% iloprost) or hypotension (8.7% placebo vs 9.0%
iloprost) between treatment groups.
Discussion
The results of ILAILL study confirm the poor clinical
outcome in elderly patients with ALLI. The combined
incidence of death and amputation in patients older
than 70 years was 27.2% in the control group. Iloprost,
as an adjuvant to surgery, significantly reduced the
combined incidence of death and amputation (pri-
mary study end-point) and mortality in this group of
high risk patients. The beneficial effect of iloprost on
the systemic component of the reperfusion syndrome
is supported by a high relative risk reduction in mor-
tality (65.9%) in treated patients. Iloprost is known to
interfere with many of the mechanisms involved in
the inflammatory response and systemic damage
following ischemia and reperfusion (i.e. through its
effects on platelet activation and blood clotting, the
reduction of free radicals and cytokines production,
Fig. 1. Incidence (%) and Hazard Ratios (HR) of major
events in the two treatment groups.
Fig. 2. Kaplan-Meier estimates of the probability of survival
in the two study groups.
197Adjuvant Iloprost in Elderly Patients with Acute Limb Ischemiaand lower expression of intercellular adhesion mole-
cules4,7e9). An early modulation of inflammatory
self-perpetuating response following ischemia and re-
perfusion by perioperative iloprost may therefore pro-
duce prompt and later benefit in patients’ outcome, as
assessed by the 3-month follow-up of ILAILL study.
Amputation incidence and the occurrence of overall
major local complications (amputationþ additional
revascularizationþ recurrent acute limb ischemia)
were quite similar in the two treatment groups (ampu-
tation 11.9% vs 10.0%, overall complications 18.4% vs
15.0% for control and treatment, respectively). These
findings are surprising given the hypothesis that
iloprost would reduce peripheral complications by im-
proving microcirculation. However, the timing of am-
putations, quite early after revascularization (median,
8 and 13 days after placebo and iloprost respectively)
seems to suggest a critical role for surgery in determin-
ing patient outcome. Moreover, the high rate of pa-
tients presenting in grade IIb-III acute limb ischemia
Table 3. Details of major clinical events in patients treated with
placebo or iloprost
Characteristic Placebo
(N¼ 92)
N.of cases
(%)
Iloprost
(N¼ 100)
N.of cases
(%)
p value
Death 14 (15.2%) 6 (6%) 0.03
Reported causes
Stroke 2 2
Acute myocardial infarction 1
Cardiac failure 2 3
Arrhytmia 1
Other thrombotic events 2
Acute renal failure 1
Bleeding 1
Pneumonia 1
Tumoral progression 1
Unknown (death at home) 3
Amputation 11 (11.9%) 10 (10%) ns
Other major cardiovascular
events
8 (8.7%) 8 (8.0%) ns
Stroke 2
Acute myocardial infarction 1
Cardiac failure 1
Arrhytmia 1
Additional revascularization 3 4
Recurrent ALLI 3 1
Table 4. Cox regression model analysis for the primary study end-
point (combined death and amputation). HR[Hazard Ratio;
CV[ cardiovascular; TE[ thromboembolectomy
Variable Effect HR 95% CI p value
Treatment Placebo vs Iloprost 1.99 1.05e3.75 0.03
Previous CV event Yes vs No 0.55 0.29e1.02 0.06
Duration of ischemia > 24 vs  24 hours 1.60 0.82e3.15 0.17
Class of ischemia  IIb vs < IIb 3.15 1.44e6.89 <0.01
Type of surgery TE vs Other 0.42 0.21e0.87 0.02(around two thirds in the two treatment groups), has
probably reduced the potential to detect an effect of
the drug. Iloprost was well tolerated in this elderly
sick population. This appears to us of relevance, since
in our study iloprost was used in emergency condi-
tions, and not in patients with chronic diseases, or as
adjuvant to elective surgery, as previously reported.10
Major complications in this study were related
to the severity of limb ischemia but not influenced
by duration of ALLI. Our study was not powered to
address these issues therefore these results have
to be considered with caution. However, the absence
of a clear relationship between duration of ischemia
and major events, together with the evidence of
a high amputation-free survival in patients with ische-
mia classified as ‘‘irreversible’’ (60.5%) seems to sup-
port a more aggressive treatment strategy in patients
with late presentation and severe peripheral ischae-
mia, particularly if referred to specialized care units
(the setting of centres participating in the ILAILL
study). A minor occurrence of complications in
patients experiencing previous cardiovascular events
seems to support the hypothesis of a less intense
inflammatory response to ischemia in atherosclerotic
‘‘stabilized’’ patients,11 and a possible influence of
a more frequent use of concomitant therapies active
at cardiovascular and metabolic levels. Furthermore,
a role for the protective effects of ischemic precondi-
tioning in humans was recently claimed in the setting
of cerebrovascular disease.12
In conclusion, our results confirm the poor clinical
outcome of ALLI, particularly in elderly patients. In
this high-risk group, iloprost as an adjuvant to sur-
gery significantly reduced the combined incidence of
death and amputation. Further data and efforts are
needed to support this finding.
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